Genova (9341) · RiskRestated
Risk of dependence on APOSTRO for manufacturing and supply
First written in FY2025. 1 of 2 entries say "Restated". Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Reliance on External Partners, Including Licensors, Sales Partners and CROsA theme 100 companies write about · 103 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2020: 8 of 42 companies on the "Worse" side.
50 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 100 companies compared. The sentences above are computed from all 100.Full recordFilings, disclosures and news, newest first
- FY2026RestatedAnnual report
「The products in our Group's smart clinic business are manufactured on a contract basis (see Important Contracts, etc. for details), and we depend on APOSTRO Co., Ltd.」
The company continues to disclose its dependence on APOSTRO for contract manufacturing and the risk of reduced supply due to orders and management strategy. - FY2025First statedAnnual report
「The products in our Group's smart clinic business are manufactured on a contract basis, and we depend on APOSTRO Co., Ltd. (formerly Shinseiki Co., Ltd.) for production of the equipment.」
The company explicitly identified, for the first time, its dependence on APOSTRO for contract manufacturing and its exclusive distribution agreement as a supply risk, and indicated a policy of addressing it through dialogue and a stronger partnership.